Prediction markets letting traders wager on clinical trial outcomes could jeopardize drug development, per a New York Times report. These platforms allow bets on whether the FDA will approve drugs for various cancers.
In This News
Concerns From Healthcare Professionals
The contracts tied to drug trials might compromise results, encourage insider trading, and undermine public trust, warn healthcare professionals. Former FDA Commissioner Robert Califf called these markets around ongoing trials a “breach of scientific conduct.” The fear is traders might influence trial participants or researchers, affecting the integrity of the data.
Participant Behavior Risks
Trial participants could alter their behavior due to financial interests. If they believe a trial won’t succeed based on market sentiment, they might drop out or misreport symptoms. Researchers, too, may unconsciously steer results based on traders’ odds. Critics argue the immense number of stakeholders involved in trials makes them ripe for insider trading.
Moral Hazards and Public Perception
A petition launched by biotechnology professional David Tsai is calling for a ban on these markets, arguing they introduce moral hazards and strain relationships between biotech firms and patient communities. The petition emphasizes that these speculative bets can distort trial data, leading to misguided confidence or skepticism about therapies. And cancer patients and clinical trial participants have voiced concerns about financial speculation tied to deeply personal outcomes. Still, especially in late-stage cancer trials, where outcomes might hinge on patient survival times, the ethical implications are profound.
What’s Next?
Regulators and relevant authorities are under pressure to address these concerns. While no immediate actions have been taken, the ongoing debate suggests this issue will remain in the spotlight, particularly with the FDA likely to weigh in on the matter soon.
Eri Gaitu leads the news desk at Best in Slot, tracking breaking developments across the gambling world in real time. From exclusive bonus offers and casino launches to licensing updates and regulatory shifts, Eri ensures readers are always first to know about the changes that matter to their gaming experience.
